Want to see GB:4BB full AI Analyst Report?
4BB Stock Chart & Stats
525.00 p
0.00 p(0.00%)
At close: 4:00 PM EDT
525.00 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range420.00 p - 920.00 p
Previous CloseN/A
Volume29.00
Average Volume (3M)999.00
Market Cap
£73.55M
Enterprise Value80.00M
Total Cash (Recent Filing)£17.80M
Total Debt (Recent Filing)£16.50M
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding15,538,518
10 Day Avg. Volume230
30 Day Avg. Volume999
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)9.43
Price to Sales (P/S)56.33
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£1,400.00Price Target Upside166.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1
Revenue Forecast (FY)£2.60M
Bulls Say, Bears Say
Bulls Say
Synthetic DNA PlatformThe proprietary cell-free DNA platform targets critical inputs for advanced therapeutics and may offer developers scalable, application-specific materials. Its relevance across several genetic-medicine applications supports potential long-term market breadth and differentiation.
Genezen Strategic CollaborationThe Genezen partnership connects 4basebio’s DNA technology with an established viral-vector manufacturing capability. This can improve commercial access, demonstrate platform utility in clinical supply chains and support adoption beyond internal development efforts.
Strengthened GovernanceAdding a director with deep-tech investment and scaling experience strengthens strategic oversight as the company commercializes its platform. Such expertise may improve partnership development, capital planning and execution in a competitive biotechnology market.
Bears Say
Persistent Loss-Making OperationsThe company has not yet converted its technology into sustainable operating profitability. Declining recent revenue and expanding losses indicate that operating costs still overwhelm gross profit, creating continued dependence on successful commercial scaling or cost reductions.
Accelerating Cash BurnPersistent negative cash generation limits the company’s ability to fund research, manufacturing and commercialization internally. Unless revenue scales meaningfully or expenses fall, continued cash consumption could require external financing and constrain strategic flexibility.
Worsening Capital StructureHigher leverage combined with a shrinking equity base reduces financial resilience and increases funding risk. A weaker balance sheet may limit investment capacity, raise reliance on new capital and heighten dilution risk while losses continue.
4basebio UK Societas News
4BB FAQ
What was 4basebio UK Societas’s price range in the past 12 months?
4basebio UK Societas lowest share price was 420.00 p and its highest was 920.00 p in the past 12 months.
What is 4basebio UK Societas’s market cap?
4basebio UK Societas’s market cap is £73.55M.
When is 4basebio UK Societas’s upcoming earnings report date?
4basebio UK Societas’s upcoming earnings report date is Sep 25, 2026 which is in 27 days.
How were 4basebio UK Societas’s earnings last quarter?
4basebio UK Societas released its earnings results on May 20, 2026. The company reported -0.586 p earnings per share for the quarter, beating the consensus estimate of -0.59 p by 0.004 p.
Is 4basebio UK Societas overvalued?
According to Wall Street analysts 4basebio UK Societas’s price is currently Undervalued.
Does 4basebio UK Societas pay dividends?
4basebio UK Societas does not currently pay dividends.
What is 4basebio UK Societas’s EPS estimate?
4basebio UK Societas’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 4basebio UK Societas have?
4basebio UK Societas has 15,538,518 shares outstanding.
What happened to 4basebio UK Societas’s price movement after its last earnings report?
4basebio UK Societas reported an EPS of -0.586 p in its last earnings report, beating expectations of -0.59 p. Following the earnings report the stock price went up 7.865%.
Which hedge fund is a major shareholder of 4basebio UK Societas?
Currently, no hedge funds are holding shares in GB:4BB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4basebio UK Societas Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£1,400.00 (166.67% Upside)
£1,400.00 (166.67% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-33.93%
Trailing 12-Months
Company Description
4basebio UK Societas
4basebio PLC, an enterprise established in 2020 and situated in Cambridge, United Kingdom, is dedicated to the entire process, from conception to delivery, of synthetic DNA and RNA products. The company also provides advanced non-viral vector solutions, with operations spanning the United States, Europe, and other international markets. Their comprehensive offerings encompass research kits, bulk enzymes, various other biological products, as well as crucial licensing and AVV manufacturing services. The company primarily caters to clients within the biotech, pharmaceutical, and contract development and manufacturing organization (CDMO) industries. Notably, the firm adopted its current name, 4basebio PLC, in July 2021, having previously been known as 4basebio UK Societas.
4BB Stock 12 Month Forecast
Average Price Target
1,400.00 p
▲(166.67% Upside)
Technical Analysis
Avacta Group plc
―
Bioventix
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
Aptamer Group Plc
―